



Chemosensory dysfunction in Cushing’s syndrome
Elena Heger1 ● German Rubinstein1 ● Leah T. Braun1 ● Stephanie Zopp1 ● Jürgen Honegger2 ● Max Seidensticker3 ●
Martin Reincke1 ● Andrea Oßwald 1
Received: 5 February 2021 / Accepted: 23 March 2021
© The Author(s) 2021
Abstract
Purpose Cushing’s syndrome (CS) can lead to structural changes in the brain and cognitive impairment, but chemosensory
function has not been investigated yet. The aim was to analyze sense of smell and taste in patients with CS and explore the
effect of therapy.
Methods The study cohort comprised 20 patients with florid CS treated between 2018 and 2020 in the outpatient clinic of
the LMU Munich. We compared these 20 patients with CS to 40 healthy subjects matched for age, sex, and smoking status.
Patients’ sense of smell and taste was examined at diagnosis and 3 months after successful therapeutic surgery leading to
clinical and biochemical remission. Odor threshold, discrimination, and identification were measured with “Sniffin’ Sticks”,
taste was measured with “Taste Strips”. Perceived sense of smell and taste was retrieved via a questionnaire.
Results Patients with florid CS had significantly reduced smell (total smell score 30.3 vs. 34.4, p < 0.0005) and taste scores
(9.5 vs. 12.0, p < 0.0005) compared to controls and significantly more frequently hyposmia (55 vs. 2.5%, p < 0.0005),
hypogeusia (40 vs. 0%, p < 0.0005), and self-reported chemosensory impairment (60 vs. 0%, p < 0.0005). Three months after
successful surgery, CS patients showed significant improvement of odor threshold (8.1 vs. 7.0, p < 0.0005), odor dis-
crimination (12.0 vs. 11.0, p= 0.003), total smell score (33.4 vs. 30.3, p < 0.0005), and taste (11.5 vs. 9.5, p= 0.003).
Conclusions Chemosensory dysfunction is a novel and clinically relevant feature of CS.
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Introduction
Excessive cortisol production causes endogenous Cushing’s
syndrome (CS). It is a severe disease with increased car-
diovascular mortality and a multitude of possible symptoms
[1]: patients mainly suffer from cardiometabolic changes
like hyperglycemia, hypertension, and central obesity. But
mental health issues and a permanent change of brain
morphology and cognitive function can occur as well [2, 3].
Consequently, patients report a decreased quality of life [4].
First-line therapy for CS is the removal of the hormone
producing tumor [5]. This requires careful diagnosis and
subtyping, as tumor location and produced hormones vary
between CS subtypes: the ACTH-dependent CS is further
subdivided into the ACTH-secreting pituitary adenoma
(Cushing’s disease (CD)) which is the most common form
of CS and the non-pituitary ectopic form (ECS). The main
subtype for ACTH-independent CS are unilateral cortisol
producing adrenal adenomas (CPA) that autonomously
produce cortisol [6].
The changes in brain structure and impairment of cognitive
function observed in CS [7] motivated us to explore changes
of smell and taste similar to neurodegenerative diseases, in
which a loss of the sense of smell and taste is associated with
disease progression and can even lead to early diagnosis
[8, 9]. Additionally, treatment with exogenous glucocorti-
coids like dexamethasone is known to lead to diminished
sense of smell and taste [10, 11]. However, this sensory
function has not been measured in patients with CS so far.
Therefore, our goal was to analyze sense of smell and
taste in CS patients and examine the effect of therapy.
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From 2018 to 2020, we recruited 20 patients with biochemi-
cally confirmed endogenous CS (Table 1), treated in the
German Cushing’s Registry CUSTODES (Cushing Syndrom:
Therapie und Outcome in Deutschland) at the Medizinische
Klinik und Poliklinik IV in Munich. All patients had newly
diagnosed, florid CS. They were tested twice: initially after
being diagnosed before any treatment, and a second time
3 month after curative surgery while being in clinical and
biochemical remission. All patients with CD underwent
endonasal-transsphenoidal surgery, all patients with CPA had
unilateral adrenalectomy and the ECS patient had an occult
source of cortisol production and underwent bilateral adrena-
lectomy. Curative surgery was defined by postoperative adre-
nal insufficiency requiring glucocorticoid replacement therapy
with hydrocortisone in physiological dose (20–25mg per day).
Patients received standard glucocorticoid replacement therapy
postoperatively, and on the day of testing the patients took
their usual morning glucocorticoid dose. Exclusion criteria
were age (<18 and >70 years), nose and neck surgery in the
last 6 months prior to diagnosis, drug abuse, and odor dis-
orders different from CS. The responsible ethics committee of
the “Medizinische Fakultät der Ludwig-Maximilians-Uni-
versität München” approved the study and all patients con-
firmed written informed consent. Additionally, we recruited a
control group of 40 healthy individuals with the same exclu-
sion criteria, matched to the patients by age-group (18–35,
36–55, >55 years), sex, and smoker/non-smoker classification.
Study protocol
Smell and taste were measured with “Sniffin’ Sticks” [12, 13],
respectively “Taste Strips” [14]. Both tests are validated in
comparison to previous test sets, show good reproducibility
and are internationally established [12, 14–22]. Additionally,
we used a questionnaire to assess perceived impairment of
smell and taste. The subjects of the control group underwent
testing in a similar fashion. For internal validation, we com-
pared the measurements of the “Sniffin’ Sticks” and “Taste
Strips” of the control group with data published by Hummel
et al. [23] and Landis et al. [16]. Thirty minutes before the
measurements, consummation of food and any drinks except
water as well as smoking was not allowed. No perfume was
allowed on the day of measurement. Measurements were
always conducted in the same odorless room.
Odor testing with “Sniffin’ Sticks”
“Sniffin’ Sticks” are felt tip pens which are filled with odors
instead of paint, which are presented 2 cm in front of the
patient’s nose with removed cap. The test set examines
scores for odor threshold (THR), odor discrimination (DIS),
and odor identification (ID). A total smell score (TDI) is
evaluated as the sum of THR, DIS, and ID. The examiner
wore odorless cotton gloves during testing. For THR and
DIS evaluation, the patients were blinded with a sleeping
mask as the correct stick had a different color.
The threshold measurement was performed with
n-butanol and patients were presented with triplets of pens.
The patient was required to identify the only odor filled
pen in each triplet, which had a different concentration
of n-butanol in each triplet [24]. Triplets were arranged
according to a single staircase method and the triplet with
the lowest concentration was presented first [18]. The THR
score can range from 1 to 16 with steps of 0.25.
In the discrimination test, the patients were presented
16 pen triplets. Each triplet contained two identical odors
and one different odor which was supposed to be identified
by the patient. The DIS score is the sum of correctly
identified pens and can range from 0 to 16 with steps of 1.
In the identification test, the patients were presented with
16 single pens. For each pen the patient had to identify the
contained odor from a choice of four common odors. The
ID score is the sum of correctly identified odors and can
range from 0 to 16 with steps of 1.
The TDI score as sum of THR, DIS, and ID can range
from 1 to 48 in steps of 0.25.
For the classification of functional hyposmia [17], we
used the updated definition of Hummel et al. [23] where
patients with TDI < 30.5 are classified as being hyposmic.
Taste testing with “Taste Strips”
“Taste Strips” are paper strips that taste sweet, sour, salty, or
bitter. The patients tasted 16 “Taste Strips” that contained the
four tastes in different concentrations [16]. Patients evaluated
each strip with closed mouth and had to make a choice for one
of the specific tastes. We used the forced-choice paradigm
introduced by Landis et al. [16], which improves the original
testing procedure from Mueller et al. [14]. The taste score is
the sum of correctly identified tastes and can range from 0 to
16 with steps of 1. The patients were allowed to drink water
between different strips. Patients were classified as hypo-
geusic, if the taste score was below 9 points [14].
Questionnaire
The questionnaire is provided by the Interdisciplinary
Center “Smell & Taste” of the University of Dresden and is
recommended by the project group “Olfactology and Gus-
tology” of the German ENT society. Questions examine
drug use, chronic illness, exposure to harmful substances,













































































































































































































































































































































































































































































































































































































































































































































































smell or taste. Finally, the questionnaire asked for perceived
reduction of both smell and taste (impaired or not impaired).
Statistical analysis
Test scores of “Sniffin’ Sticks” and “Taste Strips” were
compared with Mann–Whitney U test (patients before/after
treatment vs. control group) and Wilcoxon signed-rank test
(patients before vs. after treatment). Results are expressed as
median and quartiles. Fisher’s exact test was used to compare
binary values (hyposmia, hypogeusia, perceived impairment)
between patients and healthy controls and to examine corre-
lations between perceived impairment and hyposmia as well as
hypogeusia. Effect size of correlations was reported with
Cramer’s V. A p < 0.05 was considered statistically significant.
We calculated that we would need 15 patients and 30 controls
to have a power of 0.8 at a p level of 0.05. Assuming a
dropout rate of 25% during the study we included 20 patients
and 40 control subjects. Statistical analysis was performed
with standard statistical software (SPSS 21).
Results
We recruited 20 patients with CS (18 women, 2 men).
Thirteen patients had a diagnosis of CD, six patients of CPA,
and one patient had the ECS. The CS patients had a median
age of 45 years (25th–75th percentile: 28–57 years), 20%
were smokers. Table 1 shows the clinical characteristics of
the patients. The control group of 40 probands (36 women, 4
men) was matched according to age, sex, and smoking status.
Reduction of smell and taste in patients with CS
Patients with florid CS had drastically reduced scores of
smell (THR, DIS, ID, and total score TDI) and taste com-
pared to the healthy control group (Table 2).
Classification of absolute hyposmia and hypogeusia
showed that out of the 20 CS patients, 11 were hyposmic
and 8 were hypogeusic (Table 3), compared to 1 and 0 in
40 controls (p < 0.0005). Similarly, 12 of 20 patients
with CS reported a subjectively perceived reduction of
smell and taste at diagnosis, compared to none of the
controls (p < 0.0005). Every patient with self-reported
reduction of smell also reported a reduction of taste and
vice versa.
Improvement of sense of smell and taste 3 month
following successful surgery in CS patients
Three months after surgery we observed a significant
improvement of the taste score as well as the smell scores
THR, DIS, and TDI. Improvement of smell identification
(ID), however, did not reach statistical significance (Table 2
and Fig. 1). The taste score and the smell scores THR and
DIS equaled those of the control group, whereas smell
identification and TDI remained reduced (Table 2).
Five of the 20 patients in remission were still hyposmic
compared to a single elderly hyposmic proband in the control
group (p= 0.013, Table 3). Two patients were still classified
as hypogeusic. In addition, 8 of the 20 patients in remission
still perceived a subjective reduction of smell and taste (p <
0.0005 vs. controls).
Relation between self-reported and objective
decrease of smell and taste
All patients either reported an impairment in both smell and
taste, or reported no impairment (Fig. 2). While being
floridly cushingoid, 10 of 11 hyposmic patients also
reported a perceived impairment of smell and taste, while 7
of 9 normosmic patients reported no impairment. Three
months after successful surgery, 5 of 5 hyposmic patients
were still subjectively impaired, while 12 of 15 normosmic
Table 2 Smell and taste scores of newly diagnosed florid CS patients, cured CS patients 3 months after surgery and the control group
CS patients at diagnosis
median (25th–75th
percentile)
















TSH 7.0 (6.3–7.9) 8.1 (7.3–9.0) 8.3 (7.8–8.8) 0.000 0.000 0.403
DIS 11.0 (8.5–12.0) 12.0 (11.0–14.0) 13.0 (12.0–13.0) 0.000 0.003 0.171
ID 12.0 (11.5–14.0) 13.0 (12.0–14.0) 14.0 (13.0–15.0) 0.003 0.148 0.010
TDI 30.3 (25.3–32.9) 33.4 (30.8–35.0) 34.4 (33.6–36.6) 0.000 0.000 0.025
Taste
Taste score 9.5 (7.0–11.0) 11.5 (10.0–13.0) 12.0 (11.0–13.0) 0.000 0.003 0.103
Mann–Whitney U test was used to compare patients to the control group, while the comparison of CS patients before and after treatment was
performed with the Wilcoxon signed-rank test
TSH odor threshold, DIS odor discrimination, ID odor identification, TDI total smell score
Endocrine
patients did not report any impairment. These correlations
between perceived impairment of smell and taste and the
classification of hyposmia were significant with a large
effect size (Cramer’s V > 0.5) for both newly diagnosed
patients (p= 0.005, V= 0.698) and those following suc-
cessful surgery (p= 0.004, V= 0.707).
Five of eight hypogeusic floridly cushingoid patients
reported a perceived impairment of smell and taste, but also
seven patients with normogeusia reported impairment. After
therapy, two patients remained hypogeusic, and one reported
also a perceived impairment. Of the 18 normogeusic patients,
7 still perceived an impairment of smell and taste. Fisher’s
exact test did not detect any correlation between perceived
impairment of taste and hypogeusia (p= 1.000, V= 0.042
for florid patients; p= 1.000, V= 0.068 after surgery).
Discussion
We demonstrate that patients with florid CS suffer from
relevant impairment of smell and taste. Chemosensory
dysfunction is a novel phenotype of CS, which to the best of
our knowledge has not been described so far. Since it was a
rare finding in our matched control cohort, we believe that
self-reported decreased sense of smell and taste could be
used as an adjunct diagnostic symptom of CS.
Fig. 1 Effect of surgery on smell
and taste of individual CS
patients. TDI total smell score,
CD Cushing’s disease, CPA
cortisol producing adenoma,
ECS ectopic Cushing’s
syndrome. Effect of surgery on
smell (a) and taste (b) of
individual CS patients. TDI total
smell score, CD Cushing’s
disease, CPA cortisol producing
adenoma, ECS ectopic
Cushing’ssyndrome
Table 3 Subjective and objective impairment of smell and taste in newly diagnosed florid CS patients, cured CS patients 3 months after surgery





Control group p florid CS patients vs.
control group





12/20 (60%) 8/20 (40%) 0/40 (0%) 0.000 0.000
Objective
Hyposmia 11/20 (55%) 5/20 (25%) 1/40 (2.5%) 0.000 0.013
Hypogeusia 8/20 (40%) 2/20 (10%) 0/40 (0%) 0.000 0.107
Comparisons were performed with Fisher’s exact test
Endocrine
Successful surgical treatment partly restored perceived
and objective hyposmia and hypogeusia within 3 months.
The reversibility argues for a direct effect of glucocorticoid
excess on smell and taste sensing and against a structural
effect on the central nervous system.
A reduction of the sense of smell and taste was in our
study a frequent problem classifying 55% of patients with
florid CS as hyposmic and 40% as hypogeusic. Compared
to rheumatoid arthritis, where hyposmia has been reported
in 40% of considerably older patients [25], CS seems to
impair chemosensory function more strongly. Additionally,
60% of the patients reported a perceived impairment of both
smell and taste. Three months after successful surgery,
patients could again identify small fragrance concentrations
and were able to discriminate scents without significant
difference to the control group. The identification of dif-
ferent smells, however, remained impaired and diminished
the total smell score. Supposedly, the diminished smell
identification is mainly responsible for the remaining
hyposmia in 25% of the cured patients.
Although the significantly diminished taste score in
florid CS patients improved considerably with therapy,
40% of patients still reported perceived impairment of
taste. Notably, patients either reported no impairment or
an impairment of both smell and taste. We found a strong
correlation between hyposmia and subjective impairment
of smell as well as subjective impairment of taste: before
and after therapy 85% of the patients’ assessments of
impairment matched the hyposmia classification. How-
ever, no correlation could be found between hypogeusia
and self-reported impairment of taste. Considering that
subjective impairment of taste strongly correlates with
hyposmia, we conclude that patient’s subjective impair-
ment of taste is based on objective impairment of smell.
This supports results by Deems et al. [26], who reported
that perceived impairment of taste can usually be attrib-
uted to measured impairment of smell in the general
population. Consequently, any improvement of the sense
of smell (e.g., odor training [27]) should improve per-
ceived smell and taste in CS patients.
Peculiarly, ID as well as perceived sense of smell
remained diminished after therapy, while smell dis-
crimination and threshold recovered completely. This
implies that the reduced ID score is mainly responsible for
the remaining perceived impairment of smell. It is also
possible that the ID score generally contributes the most to
perceived impairment of smell. This seems plausible, as a
missing identification of a common odor can stand out.
This reduced sense of smell and taste in patients with
CS has not been reported previously and probably con-
tributes to the reduced quality of life reported in CS
patients [28–31].
As a correlation between impairment of smell and
depression has been reported [32], possible causes of ID
decrease and potential therapies need to be discussed.
Supraphysiologic doses of hydrocortisone and dex-
amethasone are known to alter the senses of smell and
taste [10, 11]. Consequently, it seems likely that the
cortisol excess in CS is responsible for the impairment of
smell and taste. In addition to the direct influence of
cortisol, long-term structural changes in the brains of
patients with CS [7] could be responsible for persisting
reduction of smell and taste, as an influence of gluco-
corticoids on, e.g., hippocampus and basal ganglia has
been reported [3] with, e.g., a reduced volume of the
hippocampus [2].
The impairment of smell identification might be due to a
permanent damage or a reversible damage with slow
remission. The ID score is the only measured score which
requires access to memorized scents. Consequently, if the
hippocampus, which is responsible for memory function,
is impaired due to the cortisol excess [33, 34], a reduction
of the identification of smell could be explained. Alter-
natively, patients with long lasting CS could have for-
gotten specific scents and need to relearn the identification
of these scents again. Then, odor training, which has been
Fig. 2 Correlations between
objective and subjective
impairment of smell and taste in
CS patients. Correlations
between objective and
subjective impairment of smell
(a) and taste (b) in CS patients
Endocrine
reported to improve odor discrimination and ID [27], could
be a treatment option.
Furthermore, changes in the nasal epithelium by hyper-
cortisolism could contribute to the reduced sense of smell,
as it is known that glucocorticoids reduce for example
inflammation in the nasal epithelium [35]. A nasal biopsy at
the time of transsphenoidal surgery would be interesting.
Concerning a potential linkage between the extent of
hypercortisolism and the intensity of smell and taste
impairment, we found no correlation between total smell
score (TDI) resp. total taste score and parameters of cortisol
excess at diagnosis (24 h urinary free cortisol, cortisol after
1 mg dexamethasone and late-night salivary cortisol).
Regarding Cushing subtypes, we found non-significant
differences in smell and taste scores, although patient num-
bers might have been too small for significance. Patients with
CD showed slightly better scores than CPA patients at
3 months of follow-up. Since all patients with CD underwent
endonasal-transsphenoidal surgery, the surgical procedure
appears to have no adverse effect on smell and taste [36], but
a longer follow-up might elucidate this further.
Limitations of the study
This is a monocentric explorative study with a relatively
small number of patients and a short follow-up. Whether
hyposmia and hypogeusia are fully reversible in the long-
term has to be shown by additional studies.
In conclusion, smell and taste is impaired in patients with
CS. Successful surgery is able to partly restore smell and
taste in the majority of patients.
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